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Abstract
A hallmark of several human cancers is loss of heterozygosity (LOH) of chromosome 17p13. The same chromoso-
mal region is also frequently hypermethylated in cancer. Although loss of 17p13 has been often associated with
p53 genetic alteration or Hypermethylated in Cancer 1 (HIC1) gene hypermethylation, other tumor suppressor
genes (TSGs) located in this region have critical roles in tumorigenesis. A novel TSG mapping on human chromo-
some 17p13.2 is KCTD11
REN (KCTD11). We have recently demonstrated that KCTD11 expression is frequently lost in
human medulloblastoma (MB), in part by LOH and in part by uncharacterized epigenetic events. Using a panel of
human 177 tumor samples and their normal matching samples representing 18 different types of cancer, we show
here that the down-regulation of KCTD11 protein level is a specific and a diffusely common event in tumorigen-
esis. Additionally, in order to characterize the regulatory regions in KCTD11 promoter, we identified a CpG island
and several Sp1 binding sites on this promoter, and demonstrated that Sp1 transcription factor and DNA methyla-
tion contribute, at least in part, to regulate KCTD11 expression. Our findings identify KCTD11 as a widely down-
regulated gene in human cancers, and provide a basis to understand how its expression might be deregulated in
tumor cells.
Findings
TSGs often locate at chromosomal regions, which are
frequently deleted and/or methylated in tumors. High
levels of 17p13 somatic alterations have been showed in
several tumors, distal and independent of the p53 locus
[1-4].
Our group has identified KCTD11 as an immediate-
early gene induced by neurogenic signals [5] and encod-
ing a novel adaptor of Cullin3 ubiquitin E3 ligase com-
plex targeting Histone Deacetylase 1 [6]. Importantly,
KCTD11 is a novel TSG that inhibits cell growth and is
mapping on human chromosome 17p13.2, whose
expression is frequently lost in human MB [4].
To analyze whether the down-regulation of KCTD11
represents a specific feature of MB, as well to other can-
cers, we performed a wide screening for KCTD11
expression, analyzing 177 human tumor samples and
177 normal matching samples, representing 18 different
cancer types. Normal tissues, including larynx, esopha-
gus, stomach, colon-rectum, urinary bladder, lung,
breast, gallbladder and endometrium, exhibited a
nuclear KCTD11 positive immunohistochemical staining
between 40 to 78% (Fig. 1B), whereas the matching
tumor samples showed a significant reduction of 0 to
18% of nuclear KCTD11 staining (Fig. 1A and 1B).
Reduced KCTD11 expression was not observed in thyr-
oid and kidney tumor tissues vs normal suggesting a
tumorigenic specific role of KCTD11 for the above men-
tioned tissues (Fig. 1A and 1B and data not shown).
Moreover KCTD11 was undetected both in normal and
cancer tissues from liver, lymph-node and exocrine pan-
creas (data not shown). Together, these findings clearly
indicated that selective tissues expressing KCTD11 have
down-regulated this gene during tumorigenesis.
To understand the transcriptional regulation of
KCTD11, we identified and analyzed the promoter
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r e g i o n( F i g .2 A ) .I tt u r n e do u tt ob eaT A T A -a n d
CAAT-less promoter. The transcription start site (TSS)
was previously identified [4] (Fig. 2A). Using the
TRANSFACT software, we identified six putative bind-
ing sites for Sp1 transcription factor (TF), two of them
located closely to the TSS (see Fig. 2A, Sp1-E and Sp1-
F). Sp1 is a well-characterized transcriptional activator
[7,8]. It is essential for proper expression of a large vari-
ety of genes involved in development, cell growth regu-
lation and cancer [9,10]. Moreover, Sp1 is responsible
for recruiting TATA-binding protein and fixing the TSS
at TATAless promoters [9,11]. Thus, the Sp1-E and
Sp1-F binding sites on KCTD11 promoter (Fig. 2A) are
likely to be responsible for assembling of the basal tran-
scription complex.
Figure 1 KCTD11 is down-regulated in several cancers. (A) Representative images of KCTD11 immunohistochemistry (IHC) of esophagus (a,
b), lung (c, d), stomach (e, f), colon-rectum (g, h), urinary bladder (i, j) and thyroid (k, l) (40x magnification). Tissue arrays (Super Bio Chips; cat. n.
MA, MAN, MB, MBN, MC, MCN; http://www.tissue-array.com/ver3/index.php) were incubated with 1 mg/ml affinity-purified rabbit polyclonal anti-
KCTD11 antibody, as previously described [12]. (B) Graphic representation of KCTD11 IHC analysis of tissue arrays. Normal and cancer tissues
were analyzed counting nuclear staining as percent point. 10 high power fields (hps 40x) were counted for each sample. Stromal and
inflammatory cells were not selected for nuclear staining counting. The significance of differences between normal (N) and tumor (T) tissues
means was estimated using Student’s t-test. (* indicates p < 0.005; ** indicates p < 0.001). Larinx: N n = 5, T n = 7; Esophagus: N n = 9, T n =
10; Stomach: N n = 13, T n = 10; Colon-rectum: N n = 12, T n = 10; Urinary bladder: N n = 5, T n = 9; Lung: N n = 10, T n = 10; Breast: N n = 4,
T n = 10; Gallbladder: N n = 8, T n = 6; Endometrium: N n = 7, T n = 10; Thyroid: N n = 10, T n = 10. n: number of cases for each group.
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Page 2 of 7Figure 2 Basal transcriptional activity of human KCTD11 promoter is depending on Sp1 TF. (A) Human KCTD11 promoter was identified
by Promoter Inspector http://www.genomatix.de/. Strong matches for Sp1 transcription factor binding sites are boxed. The asterisk indicates the
TSS. The CpG dinucleotides are grey highlighted and numbered. (B) Schematic representation of Luc reporter constructs driven by human full-
length KCTD11 promoter or deletion mutants. Constructs were generated by PCR using genomic DNA from peripheral blood lymphocytes as
template and specific primers [additional file 2] and subcloned in pGL3 basic vector. (C-D) Luciferase assays showing the transcriptional activity
of full-length or deletion mutants of KCTD11 promoter. 293T HEK (human embryo kidney) cell line was cultured in DMEM supplemented with
10% FCS, 2 mM L-glutamine (Sigma), 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma). 2 μgo fKCTD11-Luc reporter constructs were
transfected using Lipofectamine 2000 (Invitrogen). After 24 hrs, the cells were harvested and firefly luciferase activity was assayed using the
Firelite Dual Luminescence Reporter Gene Assay System kit (Perkin-Elmer) normalized to Renilla luciferase activity. Each experiment has been
done in triplicates. Values are the means ± S.D.
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Sp1, we analyzed the transcriptional activity of full-
length and various deleted forms of KCTD11 promoter
(Fig. 2B-D). Surprisingly, full-length KCTD11 promoter
showed a strong basal transcriptional activity (see Fig.
2C, -522/+99), as the luciferase activity was 2.5 folds
higher than that of pGL3-promoter, containing the
strong SV40 promoter. Although slightly decreased,
KCTD11 promoter activity was not drastically dropped
down by deletion of the Sp1-A, Sp1-B, Sp1-C and Sp1-
D sites, whereas it resulted strongly dependent on Sp1-E
and Sp1-F sites (Fig. 2B-C). Importantly, the interval
between Sp1-B and Sp1-C sites is too short to allow Sp1
to bind both sites, and this might explain why -398/+99
(containing Sp1-B and Sp1-C) and -338/+99 (lacking
Sp1-B) mutants showed the same transactivation ability.
Similar results have been obtained by transfecting
KCTD11 promoter constructs in other cell lines [addi-
tional file 1]. To verify the importance of Sp1-E and
Sp1-F binding sites for KCTD11 promoter activity, a
full-length KCTD11 promoter construct bearing a dele-
tion -156/-38 - the region containing the Sp1-E and
Sp1-F - was generated (Fig. 2B, -522/-157Δ-37/+99).
The deletion of Sp1-E and Sp1-F sites strongly affected
t h ea b i l i t yo fKCTD11 promoter to drive transcription
(Fig. 2D, compare -522/-157Δ-37/+99 to -522/+99).
Most likely, Sp1 binds only to one of these two sites,
considering the short interval between Sp1-E and Sp1-F
sites. To exclude that the Sp1-E upstream region -156/-
82, which was also deleted in the -522/-157Δ-37/+99
construct, was relevant to the promoter activity, we
further generated and tested an -81/+99 construct (Fig.
2B), demonstrating that this region did not have any
effect on KCTD11 transcriptional activity (Fig. 2D, com-
pare - 156/+99 and -81/+99).
Because of Sp1 protein is constitutively expressed TF
[9], to assess specifically the role of Sp1 in the regula-
tion of KCTD11 promoter, we co-transfected the
KCTD11 promoter constructs (Fig. 2B) along with Sp1,
Sp2 or Sp3 expression vectors into Drosophila Mel-2
cells (Fig. 3A), which provide a null background for Sp
TFs activity [9]. In this cellular system, none of KCTD11
promoter constructs showed basal activity when co-
transfected along with an empty vector, whereas Sp1 co-
transfection strongly activated the promoter (Fig. 3A).
Moreover, the functional significance of each Sp1 site in
the KCTD11 promoter was evaluated. Sp1-A and Sp1-C
resulted to drive KCTD11 promoter activity (Fig. 3A,
compare -398/+99 + pPac-Sp1 vs -522/+99 + pPac-Sp1
and - 268/+99 + pPac-Sp1 vs -338/+99 + pPac-Sp1),
whereas Sp1-B and Sp1-D did not (Fig. 3A, compare
-338/+99 + pPac-Sp1 vs -398/+99 + pPac-Sp1 and -156/
+99 + pPac-Sp1 vs -268/+99 + pPac-Sp1). As a control,
deletion of all Sp-1 sites completely abrogated KCTD11
promoter activation by Sp1 (Fig. 3A, -37/+99 + pPac-
Sp1 column).
As D. Mel-2 cells are null for Sp TFs, Sp1 should not
be responsible for recruiting TATA-binding protein and
fixing the TSS at TATA-less promoters in this cell con-
text. In fact, full-length KCTD11 promoter lacking Sp1-
E/Sp1-F was just slightly (30%) less active than the full-
length promoter (Fig. 3A, -522/-157Δ-37/+99 + pPac-
Sp1 vs -522/+99 + pPac-Sp1; see also Fig. 2D). There-
fore we demonstrated that the activation of KCTD11
promoter was Sp1 specific; conversely the co-transfec-
tion with Sp2 or Sp3 expression vectors failed to induce
KCTD11 promoter activity (Fig. 3A). In addition, Sp3
did not influence Sp1-driven KCTD11 transcription (Fig.
3A, left panel). Next, we demonstrated that Sp1 binds
all the Sp1 binding sites of KCTD11 promoter, except
for Sp1-D, by performing EMSAs (Fig. 3B).
Finally, we assessed the in vivo relevance of Sp1-
mediated regulation of KCTD11 gene, performing ChIP-
qPCR for Sp1, Sp3 and Acetyl-H3 on ARO cells (a thyr-
oid cancer cell line, matching a tumor tissue sample in
which KCTD11 is expressed; see Fig. 1) and HCT15
cells (a colon cancer cell line, matching a cancer type in
which KCTD11 is inhibited; see Fig. 1). As shown in
Fig. 3C, Sp1 binds to KCTD11 promoter much strongly
in ARO cells than in HCT15 cells, confirming that Sp1
plays a pivotal role in regulating KCTD11 gene expres-
sion, in vivo. At contrary, ARO and HCT15 cell lines
showed no differences in Sp3 binding to KCTD11 pro-
moter. Importantly, Acetyl-H3 binds to KCTD11 pro-
moter much strongly in ARO cells than in HCT15 cells,
indicating that this promoter is more acetylated in ARO
cells than in HCT15 cells.
These data demonstrated that Sp1 TF is necessary for
the basal transcriptional activity of KCTD11 TATA-less
promoter.
The Sp-regulated promoters are often associated with
GC-rich regions of the genome known as CpG islands,
which are important for gene regulation [12]. The pre-
sence of six Sp1 binding sites on KCTD11 promoter and
the mapping of human KCTD11 a tt h eh i g h l ym e t h y -
lated chromosomal region 17p13 prompted us to inves-
tigate the involvement of DNA methylation in KCTD11
regulation.
We found a putative CpG island overlapping almost
all KCTD11 promoter (-522 to +70), which contains 72
CpG dinucleotides (Fig. 2A; 4A). To evaluate whether
methylation might regulate KCTD11 transcription, we
investigated the effects of demethylation on KCTD11
expression, in two human colon cancer cell lines,
HCT15 and HCT116. 5′-Aza-2′-deoxycytidine (Aza)
treatment of these cells significantly increased KCTD11
mRNA level (Fig. 4B). It is worth to note that the induc-
tion of KCTD11 expression that we observed here with
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Page 4 of 7Figure 3 KCTD11 promoter is strongly activated by Sp1 TF.( A) D. Mel-2 cells (Invitrogen) were cultured in Drosophila Serum-Free Medium
(Gibco Life Technologies) plus18 mM L-glutamine (Sigma) at room temperature. KCTD11-Luc reporter constructs (1 μg) and pPac-LacZ (200 ng)
were co-transfected along with 1 μg of pPac empty vector, pPac-Sp1 or pPac-Sp2 (left panel) or pPac-Sp3 and pPac-Sp1+pPac-Sp3 (right panel)
using Cellfectin (Invitrogen). After 48 h, the cells were harvested and the luciferase activity was assayed using the Single Luciferase Assay System
(Promega), normalized to b-galactosidase activity using b-Galactosidase Enzyme Assay System (Promega). Each experiment has been done in
triplicates. Values are the means ± S.D. (B) EMSAs showing the binding of Sp1 to KCTD11 promoter. Whole extracts were prepared from 293T
HEK cells transfected with pCDNA-Sp1 (12 μg), using buffer C [16]. Cell extracts were incubated in vitro with
32P-labeled KCTD11-Sp1 probes
(Sp1-A-F) or
32P-labeled canonical Sp1 probe [additional file 2]. Binding specificity was evaluated by competition with an excess (100x) of the
cold probe or with a non-specific probe. For the supershift assays, the proteins were pre-incubated with two different anti-Sp1 antibodies (Santa-
Cruz) at 4°C for 30 min. (C) ARO (thyroid cancer) and HCT15 (colon cancer) cell line were cultured, respectively, in RPMI-1640 and DMEM
supplemented with 10% FCS. Chromatin Immunoprecipitations (ChIP) were performed by using the following antibodies: anti-Sp1 (1C6) X (sc-
420; Santa Cruz Biotech), anti-Sp3 (F-7) X (sc-28305; Santa Cruz Biotech), anti-Acetyl-Histone3 (Cell Signaling). Eluted DNA has been analyzed with
real-time q-PCR, normalized to GAPDH (left panels). Bars represent the mean of 3 independent experiments ± SD (*, p < 0.05, HCT15 versus
ARO). Total protein levels of Sp1 and Sp3 were analyzed by Western blot (right panel).
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EGF or during differentiation of cultured cerebellar
GCPs observed in previous studies and there considered
physiologically relevant [5,13]. We therefore investigated
the methylation profile of KCTD11 promoter in HCT15
and HCT116 cell lines. DNAs from sodium bisulfite-
treated HCT116 and HCT15 were amplified by PCR,
subcloned and sequenced. Sequences showed that
KCTD11 promoter is methylated in both HCT-15 and
HCT-116 cell lines with a similar pattern (Fig. 4C). As
control, DNAs from Aza and sodium bisulfite-treated
HCT116 and HCT15 cells showed, as expected, C-T
conversion of all cytosines (not shown). Together, these
data clearly demonstrate a direct role of the methylation
on KCTD11 transcriptional activity. Interestingly the
regions of KCTD11 promoter resulting methylated are
located mainly in the 5′ r e g i o n( F i g .4 C ) ,i np a r t i c u l a r
the region upstream of Sp1-A binding site (-517/-501
meaning CpGs 2 to 4), the region in between of Sp1-A
and Sp1-C binding sites (-443/-331 meaning CpGs 8 to
24) and the region upstream of Sp1-D binding site
(-279/-278 meaning CpG 30) (Fig. 2A, 4C).
Thus, the majority of the methylated CpGs in
KCTD11 promoter are not located at Sp1 binding sites,
but in the surrounding regions. To this regard, pub-
lished reports have implicated Sp1 binding sites involved
in the maintenance of the methylation-free status of the
CpG islands [12,14,15]. Thus, the balance between DNA
methylation and Sp1 binding to the promoter may
represent a mechanism to regulate the tissue-specific
expression pattern of KCTD11. It is noteworthy that the
chromosomal region 17p13, where KCTD11 localized, is
frequently hypermethylated in cancer. Therefore, the
strong down-regulation of KCTD11 in cancers (Fig. 1)
may be due to promoter hypermethylation. Of course,
we cannot exclude that other mechanisms might play a
role in the physio-pathological regulation of KCTD11
expression, such as inhibition of Sp1 activity by other
Figure 4 KCTD11 is silenced by methylation in HCT-15 and HCT-116 cell lines. A CpG island, containing 72 CpG dinucleotides (indicated by
the vertical lines) was identified from -522 bp to the +70 bp of KCTD11 promoter http://www.ebi.ac.uk/emboss/cpgplot/. (B-C) HCT-15 and HCT-
116 colorectal carcinoma cells were cultured in DMEM supplemented with 10% FCS, 2 mM L-glutamine (Sigma), 100 U/ml penicillin and 100 μg/
ml streptomycin (Sigma), and treated with 2 μM of Aza (Sigma) daily for 1 and 3 days, respectively. RNA was extracted by using Rneasy Mini Kit
(Qiagen) and cDNA was generated from 1 μg of DNase I treated RNA using MuLV Reverse Trascriptase (Applied Biosystems). (B) KCTD11 mRNA
level was analyzed by q-RT-PCR, normalized to GAPDH. The demethylating agent, Aza increased KCTD11 expression. Primers sequences are
available in additional file 2. (* indicates p < 0.005; ** indicates p < 0.001). All measurements were performed in triplicates. Values are the means
± S.D. (C) Representation of methylated CpG found in KCTD11 promoter after bisulfite treatment of HCT-15 and HCT-116 cell lines. Closed and
open boxes indicate methylated and unmethylated CpG sites, respectively. Horizontal lanes indicate methylation status of several PCR-amplified
sodium bisulfite-treated HCT-15 and HCT-116 cDNA clones. PCRs were performed using two primer sets amplifying the CpG dinucleotides from
1 to 30 and from 31 to 72 [additional file 2; arrows on Fig. 4A]. PCR products were cloned into pCRII-TOPO-TA vectors (Invitrogen) and colonies
screened by blue/white selection. Plasmid DNAs from at least ten colonies were sequenced and analyzed for C-T conversion.
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Page 6 of 7proteins. In summary, we reported a dramatic down-
expression of KCTD11 protein in several types of can-
cer. Importantly, we identified a CpG island and several
Sp1 binding sites in the KCTD11 promoter region and
further demonstrated that Sp1 transcription factor and
DNA methylation contributed, at least in part, to regu-
late KCTD11 expression. These findings provide a basis
to implicate that decreased expression of KCTD11
tumor suppressor gene is associated with cancers of spe-
cific tissue types.
Additional material
Additional file 1: KCTD11 transcriptional activity in D283, TSU and
HCT116 cell lines is comparable to the 293T KCTD11 transcriptional
activity. Luciferase assays showing the transcriptional activity of full-
length or deletion mutants of KCTD11 promoter. D283 (medulloblastoma
cell line) was cultured in Eagle’s Minimum Essential Medium and TSU
(prostate carcinoma cell line) was cultured in RPMI-1640 supplemented
with 10% FCS, 2 mM L-glutamine (Sigma), 100 U/ml penicillin and 100
μg/ml streptomycin (Sigma); HCT116 was cultured as previously
described in Figure 4. 2 μgo fKCTD11-Luc reporter constructs were
transfected using Lipofectamine 2000 (Invitrogen). After 24 hrs, the cells
were harvested and firefly luciferase activity was assayed using the
Firelite Dual Luminescence Reporter Gene Assay System kit (Perkin-Elmer)
normalized to Renilla luciferase activity. Each experiment has been done
in triplicates. Values are the means ± S.D.
Additional file 2: Table - Primer sequences for cloning KCTD11
promoter constructs, for q-PCR, for EMSA Sp1 canonic and Sp1-
KCTD11 promoter probes, for CHIP-q-PCR and for methylation
study.
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